5-chloro-3-(2-methyl-3-(trifluoromethyl)benzyl)-2-(methylthio)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one | 1374306-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-3-(2-methyl-3-(trifluoromethyl)benzyl)-2-(methylthio)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one
• CAS: 1374306-35-0
• 化学式: C₁₅H₁₂ClF₃N₄OS
• 分子量: 388.801
• InChiKey: XXGXNLRBQUNAAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.64
• 重原子数：
  25.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  52.19
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  2-甲基吗啉 、 5-chloro-3-(2-methyl-3-(trifluoromethyl)benzyl)-2-(methylthio)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one 以 乙醇 为溶剂， 反应 1.0h， 以87%的产率得到-(2-methyl-3-(trifluoromethyl)benzyl)-5-(2-methylmorpholino)-2-(methylthio)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors

  摘要：

  A series of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones with excellent enzyme inhibition, improved isoform selectivity, and excellent inhibition of downstream phosphorylation of AKT has been identified. Several compounds in the series demonstrated potent (similar to 0.100 mu M IC50) growth inhibition in a PTEN deficient cancer cell line. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.039
• 作为产物：
  描述：

  2-methylsulfanyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diol 在 potassium carbonate 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成 5-chloro-3-(2-methyl-3-(trifluoromethyl)benzyl)-2-(methylthio)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors

  摘要：

  A series of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones with excellent enzyme inhibition, improved isoform selectivity, and excellent inhibition of downstream phosphorylation of AKT has been identified. Several compounds in the series demonstrated potent (similar to 0.100 mu M IC50) growth inhibition in a PTEN deficient cancer cell line. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.039